Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Digestive Disorder

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1733905

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1733905

Gastric Motility Disorder Drugs

PUBLISHED:
PAGES: 371 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Gastric Motility Disorder Drugs Market to Reach US$72.1 Billion by 2030

The global market for Gastric Motility Disorder Drugs estimated at US$55.9 Billion in the year 2024, is expected to reach US$72.1 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Upper Digestive Tract Disorder Drugs, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$47.7 Billion by the end of the analysis period. Growth in the Lower Digestive Tract Disorder Drugs segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$15.2 Billion While China is Forecast to Grow at 8.0% CAGR

The Gastric Motility Disorder Drugs market in the U.S. is estimated at US$15.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$14.9 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Gastric Motility Disorder Drugs Market - Key Trends & Drivers Summarized

Why Are Gastric Motility Disorders Gaining Attention in Gastroenterology?

Gastric motility disorders, which involve abnormal movement or dysfunction of the digestive tract, are increasingly being recognized as a significant factor in a wide range of gastrointestinal conditions. These disorders can cause a variety of symptoms, including bloating, nausea, vomiting, abdominal pain, and irregular bowel movements, which can severely affect a patient's quality of life. Diseases such as gastroparesis, where the stomach empties too slowly, and functional dyspepsia, which involves discomfort in the upper abdomen, are among the most common gastric motility disorders. These conditions are becoming more prevalent, largely due to changing lifestyles, increasing rates of chronic diseases such as diabetes, and an aging population that is more prone to gastrointestinal disorders. In addition, the increasing awareness of the connection between gastric motility dysfunction and diseases such as irritable bowel syndrome (IBS) and gastroesophageal reflux disease (GERD) has prompted a growing interest in treating these conditions. The rising prevalence of gastric motility disorders, combined with the significant impact these diseases have on patients' health and well-being, has led to greater investment in research and development for more effective treatments. As a result, the gastric motility disorder drug market is witnessing increased innovation and expansion, aiming to provide patients with more tailored and effective therapeutic options.

How Are Advances in Drug Development Enhancing Treatment for Gastric Motility Disorders?

Advancements in drug development are playing a critical role in improving the treatment options available for gastric motility disorders, providing patients with more effective and personalized therapies. Traditionally, treatment for gastric motility disorders was limited to non-specific interventions such as dietary changes and the use of prokinetic agents, which help stimulate the movement of the stomach and intestines. However, recent progress in pharmacology has led to the development of new classes of drugs designed to target the underlying mechanisms causing gastric motility dysfunction. For example, the use of serotonin agonists, which target specific receptors in the gut, has shown promising results in improving gastric motility in conditions such as gastroparesis and functional dyspepsia. Additionally, motilin receptor agonists, such as the drug erythromycin, are being studied and refined to improve gastric emptying times and reduce symptoms like nausea and bloating. Another area of advancement is the development of selective dopamine receptor antagonists, which can reduce gastric stasis and improve overall motility without the common side effects seen in earlier treatments. The growing focus on personalized medicine, where treatments are tailored based on the patient’s genetic and physiological characteristics, is also influencing the development of drugs for gastric motility disorders. Furthermore, clinical trials are focusing on combining different drug therapies to address multiple factors contributing to these disorders, such as gastrointestinal inflammation, gut microbiota imbalance, and altered neural signaling. These advances in drug development are not only offering new treatment options but are also paving the way for more targeted and effective interventions, improving patient outcomes and quality of life.

What Are the Key Factors Contributing to the Growth of the Gastric Motility Disorder Drugs Market?

The gastric motility disorder drugs market is growing due to several key factors, including the increasing prevalence of gastrointestinal disorders, the aging population, and a deeper understanding of the pathophysiology behind these conditions. As the global population ages, there is a growing incidence of gastric motility disorders, particularly conditions like gastroparesis, which are more common among older adults. Additionally, diseases such as diabetes, which is often associated with nerve damage affecting gastric motility, are becoming more widespread, further increasing the demand for treatments. The global rise in obesity rates is also contributing to the increase in gastrointestinal disorders, as excess weight can exacerbate motility issues. Moreover, the increasing recognition of the role of gastric motility disorders in the overall digestive health landscape is driving greater awareness and research in this field. Advances in diagnostic tools, such as high-resolution manometry and gastric emptying studies, have also improved the ability to identify motility issues early, allowing for more targeted treatment strategies. Healthcare professionals and patients are becoming more aware of the impact of gastric motility disorders on overall health, leading to more people seeking treatment for these often-overlooked conditions. The increasing availability of innovative drugs, such as prokinetic agents and targeted therapies, has also contributed to market growth by providing patients with more effective options for managing their symptoms. The combination of these factors is fueling the expansion of the gastric motility disorder drugs market, as patients, healthcare providers, and pharmaceutical companies work together to address the growing need for better treatments.

What Are the Key Drivers Behind the Growth of the Gastric Motility Disorder Drugs Market?

The growth of the gastric motility disorder drugs market is driven by several key factors related to medical research, technological advancements, and rising healthcare awareness. One of the main drivers is the increasing prevalence of gastric motility disorders, particularly in countries with aging populations. As people age, they are more likely to develop conditions such as gastroparesis or functional dyspepsia, which require specialized drug treatments. The rise in lifestyle-related diseases, particularly diabetes and obesity, which are often linked to motility disorders, is another significant factor driving market growth. The ongoing improvements in diagnostic tools are helping healthcare providers detect these conditions earlier and more accurately, allowing for earlier intervention and more effective drug treatments. Furthermore, the shift toward personalized medicine, where treatments are tailored to an individual’s specific needs based on genetic and physiological characteristics, is creating opportunities for the development of more effective and targeted therapies for gastric motility disorders. Another important factor is the increasing investment in research and development by pharmaceutical companies to create new and more effective drugs for these conditions. This has led to the introduction of several new drug classes, such as serotonin and motilin receptor agonists, which target the underlying mechanisms of motility dysfunction more precisely than older medications. Additionally, the growing awareness of the impact of gastric motility disorders on quality of life is driving demand for better treatment options, pushing the market to expand. With more effective treatments on the horizon and an increasing focus on patient-centered care, the gastric motility disorder drugs market is expected to continue its growth trajectory, improving patient outcomes and reducing the burden of these conditions on public health systems.

SCOPE OF STUDY:

The report analyzes the Gastric Motility Disorder Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disorder Type (Upper Digestive Tract, Lower Digestive Tract); Drug Class (Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors, Other Drug Classes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AbbVie Inc.
  • Abbott Laboratories
  • Akums Drugs and Pharmaceuticals
  • AstraZeneca plc
  • Bayer AG
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Cadila Pharmaceuticals
  • Cipla Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • Evoke Pharma
  • Ferring Pharmaceuticals
  • Janssen Pharmaceuticals
  • Mallinckrodt Pharmaceuticals
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP33883

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Gastric Motility Disorder Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Gastric Motility Disorders Drives Demand for Targeted Pharmacological Treatments
    • Here's the Story: How Advancements in Drug Development are Expanding Treatment Options for Gastric Motility Disorders
    • Growing Awareness of Digestive Health and its Impact on Quality of Life Fuels Market Demand for Gastric Motility Disorder Drugs
    • Increasing Adoption of Personalized Medicine in Gastroenterology Strengthens the Business Case for Tailored Therapies
    • Surge in Cases of Functional Gastrointestinal Disorders (FGIDs) and Irritable Bowel Syndrome (IBS) Expands the Addressable Market
    • Advancements in Prokinetic and Antispasmodic Drug Formulations Improve Patient Outcomes and Satisfaction
    • Here's How the Shift Toward Non-Invasive Treatment Options Is Spurring Demand for Oral Medications for Gastric Motility
    • Rising Demand for Combination Therapies Enhances Treatment Efficacy and Market Opportunities for Gastric Motility Drugs
    • Increasing Focus on Gastrointestinal Health Management Drives Market for Symptom-Specific Drugs
    • Growing Research into Gut-Brain Interactions Opens New Pathways for Novel Gastric Motility Disorder Therapies
    • Rising Popularity of Over-the-Counter Remedies and Dietary Supplements Creates Opportunities for Non-Prescription Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Gastric Motility Disorder Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Gastric Motility Disorder Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Gastric Motility Disorder Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Upper Digestive Tract by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Upper Digestive Tract by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Upper Digestive Tract by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Lower Digestive Tract by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Lower Digestive Tract by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Lower Digestive Tract by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Antacids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Antacids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Antacids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Antidiarrheals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Antidiarrheals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Antidiarrheals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Calcium-channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Calcium-channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Calcium-channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for H2 Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for H2 Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for H2 Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Proton Pump Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Proton Pump Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Proton Pump Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gastric Motility Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • JAPAN
    • Gastric Motility Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • CHINA
    • Gastric Motility Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • EUROPE
    • Gastric Motility Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Gastric Motility Disorder Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Gastric Motility Disorder Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • FRANCE
    • Gastric Motility Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • GERMANY
    • Gastric Motility Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Gastric Motility Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Gastric Motility Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Gastric Motility Disorder Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Gastric Motility Disorder Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Gastric Motility Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • INDIA
    • Gastric Motility Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Gastric Motility Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Gastric Motility Disorder Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Gastric Motility Disorder Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Gastric Motility Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Gastric Motility Disorder Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Gastric Motility Disorder Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
  • AFRICA
    • Gastric Motility Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Gastric Motility Disorder Drugs by Disorder Type - Upper Digestive Tract and Lower Digestive Tract Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Gastric Motility Disorder Drugs by Disorder Type - Percentage Breakdown of Value Sales for Upper Digestive Tract and Lower Digestive Tract for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Gastric Motility Disorder Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Gastric Motility Disorder Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Gastric Motility Disorder Drugs by Drug Class - Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Gastric Motility Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!